188 related articles for article (PubMed ID: 30913210)
1. Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era.
Charrow A; Xia FD; Lu J; Waul M; Joyce C; Mostaghimi A
PLoS One; 2019; 14(3):e0210445. PubMed ID: 30913210
[TBL] [Abstract][Full Text] [Related]
2. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States.
Pinheiro SP; Kang EM; Kim CY; Governale LA; Zhou EH; Hammad TA
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1251-7. PubMed ID: 23913625
[TBL] [Abstract][Full Text] [Related]
3. Isotretinoin for acne and rosacea.
Watson KD; Miest RY; Tollefson MM
Semin Cutan Med Surg; 2016 Jun; 35(2):79-86. PubMed ID: 27416313
[TBL] [Abstract][Full Text] [Related]
4. Abnormal Baseline Lab Results Rarely Lead to Treatment Modification for Patients on Isotretinoin.
Tkachenko E; Sharma P; Mostaghimi A
Dermatology; 2020; 236(6):517-520. PubMed ID: 32069457
[TBL] [Abstract][Full Text] [Related]
5. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system.
Shin J; Cheetham TC; Wong L; Niu F; Kass E; Yoshinaga MA; Sorel M; McCombs JS; Sidney S
J Am Acad Dermatol; 2011 Dec; 65(6):1117-25. PubMed ID: 21565419
[TBL] [Abstract][Full Text] [Related]
6. We Pledge to Change iPLEDGE.
Pierson JC; Ferris LK; Schwarz EB
JAMA Dermatol; 2015 Jul; 151(7):701-2. PubMed ID: 25853235
[No Abstract] [Full Text] [Related]
7. Gender differences in isotretinoin prescriptions during the COVID-19 pandemic at a U.S. academic medical center.
Duan GY; Ruiz de Luzuriaga AM
Arch Dermatol Res; 2023 Apr; 315(3):643-645. PubMed ID: 36149480
[TBL] [Abstract][Full Text] [Related]
8. Can we ensure the safe use of known human teratogens?: The iPLEDGE test case.
Honein MA; Lindstrom JA; Kweder SL
Drug Saf; 2007; 30(1):5-15. PubMed ID: 17194167
[TBL] [Abstract][Full Text] [Related]
9. Simplifying contraception requirements for iPLEDGE: A decision analysis.
Barbieri JS; Roe AH; Mostaghimi A
J Am Acad Dermatol; 2020 Jul; 83(1):104-108. PubMed ID: 32068040
[TBL] [Abstract][Full Text] [Related]
10. Administrative Burden of iPLEDGE Deters Isotretinoin Prescriptions: Results From a Survey of Dermatologists.
Lee G; Wolf JR; Somers KE
Cutis; 2022 Jul; 110(1):44-47. PubMed ID: 36179224
[TBL] [Abstract][Full Text] [Related]
11. Circumventing iPLEDGE: Circumventing ethical responsibility?
Lee KC; Bercovitch L
J Am Acad Dermatol; 2017 Dec; 77(6):1185-1187. PubMed ID: 29132856
[No Abstract] [Full Text] [Related]
12. Isotretinoin: controversies, facts, and recommendations.
Bauer LB; Ornelas JN; Elston DM; Alikhan A
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1435-1442. PubMed ID: 27414637
[TBL] [Abstract][Full Text] [Related]
13. Isotretinoin: update on controversial issues.
Prevost N; English JC
J Pediatr Adolesc Gynecol; 2013 Oct; 26(5):290-3. PubMed ID: 24147278
[TBL] [Abstract][Full Text] [Related]
14. High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life.
Cyrulnik AA; Viola KV; Gewirtzman AJ; Cohen SR
Int J Dermatol; 2012 Sep; 51(9):1123-30. PubMed ID: 22909370
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin.
Rademaker M
Australas J Dermatol; 2010 Nov; 51(4):248-53. PubMed ID: 21198520
[TBL] [Abstract][Full Text] [Related]
16. A comparative review of the isotretinoin pregnancy risk management programs across four continents.
Kovitwanichkanont T; Driscoll T
Int J Dermatol; 2018 Sep; 57(9):1035-1046. PubMed ID: 29508918
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of clinical adverse effects and laboratory alterations in patients with acne vulgaris treated with oral isotretinoin.
Brito Mde F; Sant'Anna IP; Galindo JC; Rosendo LH; Santos JB
An Bras Dermatol; 2010; 85(3):331-7. PubMed ID: 20676466
[TBL] [Abstract][Full Text] [Related]
18. Acute acne flare following isotretinoin administration: potential protective role of low starting dose.
Borghi A; Mantovani L; Minghetti S; Virgili A; Bettoli V
Dermatology; 2009; 218(2):178-80. PubMed ID: 19060474
[No Abstract] [Full Text] [Related]
19. Isotretinoin systemic therapy and the shadow cast upon dermatology's downtrodden hero.
Lowenstein EB; Lowenstein EJ
Clin Dermatol; 2011; 29(6):652-61. PubMed ID: 22014987
[TBL] [Abstract][Full Text] [Related]
20. A retrospective evaluation of routine isotretinoin laboratory monitoring in patients older than 35 years.
Sharma P; Tkachenko E; Mostaghimi A
J Am Acad Dermatol; 2021 Jan; 84(1):201-202. PubMed ID: 32344069
[No Abstract] [Full Text] [Related]
[Next] [New Search]
